10x Genomics Unveils Xenium Protein: A Revolutionary Spatial Multiomic Assay for Simultaneous RNA and Protein Analysis
ByAinvest
Tuesday, Aug 19, 2025 9:03 am ET1min read
TXG--
Xenium Protein, the first fully integrated spatial multiomic workflow from 10x Genomics, allows researchers to analyze RNA and protein data together in a single automated run. This eliminates the need for complex data integration and enhances precision. The technology is designed to streamline workflows and accelerate discoveries by combining data from multiple technologies into a single experiment.
The initial subpanels included in Xenium Protein are tailored to study well-characterized proteins involved in cell growth, signaling, and immune response. These subpanels are valuable for investigating complex diseases such as cancer and immunology. By reducing the need for separate workflows and sample sections, Xenium Protein simplifies experimental design and speeds up the pace of valuable discoveries through multiomic analysis.
Early access customers are leveraging Xenium Protein for early discovery, translational research, and large-scale atlasing efforts. Dr. Julien Tessier, Principal Scientist at Sanofi, highlights the benefits of this integrated multiomics approach: "It removes the reliance on data co-registration, which can introduce uncertainty, while delivering critical insights into target and biomarker expression that RNA alone often fails to capture" [2].
Xenium Protein is now available globally, further expanding 10x Genomics' suite of tools designed to advance human health. The company's integrated research solutions, including instruments, consumables, and software, have been instrumental in breakthroughs across oncology, immunology, and neuroscience, fueling powerful discoveries that transform our understanding of health and disease.
References:
[1] https://www.marketscreener.com/news/10x-genomics-launches-xenium-protein-advancing-spatial-biology-by-enabling-same-cell-rna-and-protei-ce7c51dddb8fff20
[2] https://www.prnewswire.com/news-releases/10x-genomics-launches-xenium-protein-advancing-spatial-biology-by-enabling-same-cell-rna-and-protein-analysis-302532774.html
10x Genomics has launched Xenium Protein, a spatial multiomic assay that enables simultaneous RNA and protein detection in the same cell, on the same tissue section. This fully integrated workflow simplifies experimental design, shortens time to results, and unlocks deeper insights into cell function and disease biology. Initial subpanels include dozens of well-characterized proteins involved in cell growth, signaling, and immune response, valuable for studying cancer, immunology, and other complex disease areas.
Pleasanton, Calif. — 10x Genomics, Inc. (Nasdaq: TXG), a leading innovator in single cell and spatial biology, has announced the launch of Xenium Protein, a groundbreaking spatial multiomic assay that enables simultaneous RNA and protein detection in the same cell and tissue section. This integrated workflow, part of the Xenium Spatial platform, simplifies experimental design, shortens time to results, and offers deeper insights into cell function and disease biology [1].Xenium Protein, the first fully integrated spatial multiomic workflow from 10x Genomics, allows researchers to analyze RNA and protein data together in a single automated run. This eliminates the need for complex data integration and enhances precision. The technology is designed to streamline workflows and accelerate discoveries by combining data from multiple technologies into a single experiment.
The initial subpanels included in Xenium Protein are tailored to study well-characterized proteins involved in cell growth, signaling, and immune response. These subpanels are valuable for investigating complex diseases such as cancer and immunology. By reducing the need for separate workflows and sample sections, Xenium Protein simplifies experimental design and speeds up the pace of valuable discoveries through multiomic analysis.
Early access customers are leveraging Xenium Protein for early discovery, translational research, and large-scale atlasing efforts. Dr. Julien Tessier, Principal Scientist at Sanofi, highlights the benefits of this integrated multiomics approach: "It removes the reliance on data co-registration, which can introduce uncertainty, while delivering critical insights into target and biomarker expression that RNA alone often fails to capture" [2].
Xenium Protein is now available globally, further expanding 10x Genomics' suite of tools designed to advance human health. The company's integrated research solutions, including instruments, consumables, and software, have been instrumental in breakthroughs across oncology, immunology, and neuroscience, fueling powerful discoveries that transform our understanding of health and disease.
References:
[1] https://www.marketscreener.com/news/10x-genomics-launches-xenium-protein-advancing-spatial-biology-by-enabling-same-cell-rna-and-protei-ce7c51dddb8fff20
[2] https://www.prnewswire.com/news-releases/10x-genomics-launches-xenium-protein-advancing-spatial-biology-by-enabling-same-cell-rna-and-protein-analysis-302532774.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet